October 6, 2014
CLEVELAND—Ganeden Biotech’s GanedenBC30 (Bacillus coagulans GBI-30, 6086) probiotic ingredient received approval by food and drug authorities in four significant Asian markets: Japan, India, Taiwan and the Philippines.
GanedenBC30 is available as a result of the established partnerships between Maypro Industries in Japan and Connell Bros. Company in India, Taiwan and the Philippines.
"Japan, Taiwan, Philippines and India are significant markets within Asia, where the consumers are already familiar with the benefits of probiotics," said Stephen Quinn, international business development and regulatory manager of Ganeden Biotech. "The regulatory approvals provide a great deal of opportunity for probiotic innovation within these thriving functional food and beverage markets, and we are thrilled to be able to introduce the unique formulating capabilities of GanedenBC30."
On October 15 to 17, Ganeden Biotech will be exhibiting in conjunction with Connell Bros. at Food Ingredients Asia in Jakarta, Indonesia (booth F21). Also, visit the "Food for a Quality Life" conference on October 16 to hear Quinn speak during the "Advances in Nutrition and Health" track about Bacillus coagulans -A spore forming bacteria as novel probiotics in Asia.
Earlier this year, Ganeden Biotech received a new patent, which covers probiotic Bacillus coagulans in all coffee, tea and cereal including GanedenBC30 (U.S. Patent #8,697,055 B2).
You May Also Like
Sep 28, 2023
Innovation in stress and sleep management: Holixer™– white paperSep 22, 2023
Probi study finds subjects’ brains worked better under stress with probioticSep 29, 2023
Cognitive health growth comes out on top: A range of solutions for diverse needs continue to emerge and win – product development guideSep 25, 2023
LifeVantage proxy fight heats up as revenues coolSep 28, 2023